生物活性：Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3][4].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Rufinamide-d2 相关抗体:
xCT Antibody (YA006)
xCT Antibody (YA652)
Alpha-ENaC Antibody
CRMP2 Antibody (YA3370)
SLC12A1 Antibody (YA1403)
CRMP1 Antibody (YA1941)
CRMP5 Antibody (YA2497)
CRMP3 Antibody (YA2563)
CRMP4 Antibody (YA2777)
分子量：240.21
Formula：C10H6D2F2N4O
CAS 号：1129491-38-8
非标记 CAS：106308-44-5
中文名称：卢非酰胺-d2
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Chen JL, et.al. Inhibition of resurgent Na+ currents by rufinamide. Neuropharmacology. 2024 Apr 1;247:109835.
 [Content Brief]
[3]. White HS, et.al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.
 [Content Brief]
[4]. Suter MR, et.al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72.
 [Content Brief]